Subscribe To
Should you buy eli lilly stock now?
Eli Lilly announced the successful results of a phase 3 trial with donanemab, an experimental treatment...
May 4, 2023, 5:13 am
Microsoft doubles down on ai with new bing features
Microsoft is embarking on the next phase of Bing's expansion. And — no surprise — it heavily revolv...
May 4, 2023, 3:00 am
Attack on kremlin risks escalation of ukraine war
A pair of drones attacked Putin's residence at the Kremlin early today and though both were shot down, they may herald a new ...
May 3, 2023, 4:24 pm
Immunogen stock price doubles after ovarian cancer candidate elahere aces phase 3 study
ImmunoGen Inc stock more than doubled after the company shared positive topline data from the phase 3 c...
May 3, 2023, 12:36 pm
Prophase labs’ linebacker-1 cancer therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including l
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) — Prophase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”),...
May 3, 2023, 12:30 pm
Cingulate announces successful transfer of ctx-1301 (dexmethylphenidate) proprietary ptr™ manufacturing processes to societal cdmo
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for ...
May 3, 2023, 10:45 am
Why is immunogen (imgn) stock up 125% today?
ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a phase ...
May 3, 2023, 10:04 am
Eli lilly's alzheimer's drug slowed cognitive decline in phase 3 study
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's Alzheimer's treatment donanemab, which slowed disease progression in the ...
May 3, 2023, 9:56 am
Adobe's $20b figma acquisition falls on uk antitrust radar
The U.K.'s competition authority is adding Adobe's proposed $20 billion bid for digital design rival Figma to its ever-growing to-do list. The Competi...
May 3, 2023, 9:55 am
Eli lilly stock jumps on positive alzheimer's drug phase 3 trial data
The company says a phase 3 study shows that donanemab 'significantly slowed cognitive and functional de...
May 3, 2023, 6:34 am
Eli lilly stock jumps 4% premarket on news of positive results in late-stage trial of alzheimer's disease treatment
Eli Lilly & Co.'s stock LLY jumped 4% premarket Wednesday, after the company announced positive data from a late-stage trial of its Alzheimer's diseas...
May 3, 2023, 6:14 am
2 explosive stocks to buy without hesitation in 2023 and hold for at least a decade
An advertising giant and a fintech disruptor each may present compelling buy opportunities for long-term investors. Pinterest is capitalizing on mobil...
May 3, 2023, 5:45 am
Is it time to buy the s&p 500's 3 worst-performing april stocks?
Drugmaker Catalent saw production challenges a company of its caliber shouldn't be facing. Enphase Ener...
May 3, 2023, 5:31 am
Prophase labs, inc. (prph) surges 8.5%: is this an indication of further gains?
Prophase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The late...
May 3, 2023, 5:20 am
Tscan therapeutics announces upcoming trial in progress poster presentation at the american society of gene and cell therapy 26th annual meeting
Company to host a virtual event to discuss highlights from its phase 1 umbrella trial of TSC-100 and TS...
May 2, 2023, 8:42 pm
Cellectis announces oral presentation on ameli-01 and poster presentation on multiplex engineering for superior generation of car t-cells at the american society of gene and cell therapy (asgct) annua
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology co...
May 2, 2023, 8:35 pm
2seventy bio to present new preclinical and clinical data from broad portfolio of investigational cell therapies at the asgct 26th annual meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation...
May 2, 2023, 4:37 pm
Travere therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug
Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statis...
May 2, 2023, 12:50 pm
Sidus space signs mou with lulav space for guidance navigation and control solution for lunar missions
Sidus Space Inc (NASDAQ:SIDU) said it will be providing a complete guidance navigation and control solution (GN&C) for lunar satellite and lunar land...
May 2, 2023, 11:33 am
Astrazeneca fda vote worth potentially us$500mln annual peak sales
AstraZeneca PLC (LSE:AZN) forecasts for its major Lynparza drug are expected to be trimmed following an advisory vote against full approval in the US...
May 2, 2023, 10:45 am